BOSTON & LYON, France--(BUSINESS WIRE)--Regulatory News:
ERYTECH Inc., the US affiliate of ERYTECH Pharma (Euronext Paris: ERYP) (Paris:ERYP) (ADR:EYRYY), the French biopharmaceutical company that develops innovative 'tumor starvation' treatments for acute leukemia and other oncology indications with unmet medical needs, announces the appointment of Iman El-Hariry as Chief Medical Officer, responsible for global medical, clinical and regulatory affairs.